Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Low dose AAV8-FVIII gene therapy on Chinese severe Hemophilia A patients with sustainable efficacy and safety

Wei Liu, Xinyue Dai, Feng Xue et al. Nov 03, 2025 pp. 4317-4317 10.1182/blood-2025-4317

Abstract Introduction: Hemophilia A is an X-linked (FⅧ gene mutation) disorder of hemostasis that results in insufficient endogenous factor...

Efficacy and safety of gecacitinib in thrombocytopenic myelofibrosis patients

Yi Zhang, Hu Zhou, Junling Zhuang et al. Nov 03, 2025 pp. 2028-2028 10.1182/blood-2025-2028

Abstract Introduction Despite recent advances in treating myelofibrosis (MF)-associated splenomegaly and symptoms, disease- and treatment-as...

A defined culture model for ex vivo expansion of primary AML cells preserves leukemic stem cells and clonal architecture for functional and therapeutic studies

Charyguly Annageldiyev, Upendar Golla, Satyam Patel et al. Nov 03, 2025 pp. 3488-3488 10.1182/blood-2025-3488

Abstract First three authors contributed equally. Introduction: Acute myeloid leukemia (AML) is highly heterogeneous, and its ex vivo cultur...

Impact of 7-day versus standard venetoclax exposure in combination with azacitidine in frontline AML settings: A real-world analysis from the venaura retrospective multicenter study

Gaspar Aspas Requena, Pedro Chorao, Samy Chraibi et al. Nov 03, 2025 pp. 3398-3398 10.1182/blood-2025-3398

Abstract Background: Azacitidine (AZA) plus venetoclax (VEN) is the standard first-line treatment for patients with acute myeloid leukemia (A...

Aplastic anemia in pregnancy: A case series review of hematologic parameters, treatment, and maternal-fetal outcomes

Selma EL Jabbouri, Ronald Go Nov 03, 2025 pp. 1422-1422 10.1182/blood-2025-1422

Abstract Introduction: Aplastic anemia (AA) affects approximately 1 in a million people per year in the United States and can present as a n...

Reduced intensive chemotherapy combined with venetoclax in adult patients with Acute Myeloid Leukemia: A retrospective single-center analysis

Jingwen Li, Xueping Luo, Junqing Wu et al. Nov 03, 2025 pp. 6908-6908 10.1182/blood-2025-6908

Abstract Background Intensive induction chemotherapy combination improves response rates in adult patients with acute my...

Evaluation of real-world outcomes among CLL patients based on sequencing of BTKi and BCL2i therapies

Taral Patel, Rushir Choksi, Tejvir Singh et al. Nov 03, 2025 pp. 6286-6286 10.1182/blood-2025-6286

Abstract Background: Current first-line (1L) therapies for chronic lymphocytic leukemia (CLL) consist of Bruton tyrosine kinase inhibitors (...

Early-stage nodular lymphocyte predominant Hodgkin lymphoma: Disease characteristics, treatment pattern, and long-term outcomes from a tertiary care cancer institute in India

Bhausaheb Bagal, Jayant Goda, Ankita Kanoja et al. Nov 03, 2025 pp. 5404-5404 10.1182/blood-2025-5404

Abstract Background: Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a rare & distinct subtype of Hodgkin...

Tocilizumab for cytokine release syndrome after allogeneic hematopoietic stem cell transplantation with post-transplant cyclophosphamide

Tuan Phan, Evandro Bezerra, Hannah Choe et al. Nov 03, 2025 pp. 4217-4217 10.1182/blood-2025-4217

Abstract Background: Post-transplant cyclophosphamide (PTCy)-based allogeneic hematopoietic stem cell transplantation (alloHCT) is frequentl...

Arsenite and its primary metabolite monomethylarsonous acid impair early human red blood cell development

Lauren Heine, Ana Armijo, Grace Picha et al. Nov 03, 2025 pp. 2883-2883 10.1182/blood-2025-2883

Abstract Abstract: Chronic exposure to heavy metals, including arsenic, is linked to hematological disorders such as anemia. Both in vivo an...

Clinical and microbiological insights into invasive fusariosis following allogeneic hematopoietic stem cell transplantation: A 15-year single-center analysis

Jotaro Yamamoto, Shinsuke Takagi, Sho Ogura et al. Nov 03, 2025 pp. 2492-2492 10.1182/blood-2025-2492

Abstract Introduction: Invasive fusariosis (IF) is a rare but life-threatening fungal infection that mainly affects immunocompromised patien...

Atypical IGH::CCND1 rearrangements by fluorescent in situ hybridization are associated with higher risk cytogenetic features in multiple myeloma

Changqing Xia, Zhenya Tang, Weiwei Zhang et al. Nov 03, 2025 pp. 5783-5783 10.1182/blood-2025-5783

Abstract Background: The IGH::CCND1 rearrangement, resulting from a translocation between chromosomes 11q13 and 14q32, is one of the most co...

Autologous hematopoietic stem cell transplantation combined with inaticabtagene autoleucel in adults with high-risk B-cell acute lymphoblastic leukemia: Interim analysis of a phase II study

Erlie Jiang, Rongli Zhang, Aiming Pang et al. Nov 03, 2025 pp. 5929-5929 10.1182/blood-2025-5929

Abstract Introduction: Autologous hematopoietic stem cell transplantation (auto-HSCT) is an effective treatment option for patients with adu...

The recombinant adjuvant zoster vaccine induces similar immune responses in ruxolitinib-treated patients with myelofibrosis and polycythemia vera

Beatriz Astibia-Mahillo, Valentina Leguizamon, Elena Mateos et al. Nov 03, 2025 pp. 7273-7273 10.1182/blood-2025-7273

Abstract Introduction: Patients with myeloproliferative neoplasms (MPN) such as myelofibrosis (MF) or polycythemia vera (PV) who are receivi...

Age at diagnosis drives molecular pathology and prognosis in diffuse large B-cell lymphoma

Rabsa Sikder, Vivian Zheng, Kara Kelly et al. Nov 03, 2025 pp. 1883-1883 10.1182/blood-2025-1883

Abstract Background: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma with significant pathological...

Longitudinal analysis of MRD negativity and immune dynamics in patients with transplant-ineligible newly diagnosed multiple myeloma treated with iberdomide, daratumumab, and dexamethasone from the CC-220-MM-001 trial

Danny Jeyaraju, Sanhita Sengupta, Paulo Maciag et al. Nov 03, 2025 pp. 2255-2255 10.1182/blood-2025-2255

Abstract Introduction: Iberdomide (IBER) is an oral CELMoD™ agent with optimized cereblon binding leading to improved direct antitumor and i...

Evaluation of the combined effects of emicizumab and marstacimab in plasma from Hemophilia A patients using thrombin generation assay

Michela Ronconi, Peter Groß, Andrew Palladino et al. Nov 03, 2025 pp. 4834-4834 10.1182/blood-2025-4834

Abstract Background: Patients with Hemophilia A (HA) may be treated with prophylactic emicizumab therapy, a bispecific monoclonal antibody t...

Decitabine enhances tumor immunogenicity via transposable element reactivation but concurrently induces oncogene expression in Acute Myeloid Leukemia

Dharambir Kashyap, Riya Sharma, Malak Khalife et al. Nov 03, 2025 pp. 6766-6766 10.1182/blood-2025-6766

Abstract Background: Decitabine (DCB), a DNA methyltransferase inhibitor used in the treatment of acute myeloid leukemia (AML), induces glob...

Hospitalization and thromboembolic outcomes in patients with immune thrombocytopenic purpura and celiac disease: A retrospective cohort study

Manas Pustake, Kunal Sharma, Lakshmi Kattamuri et al. Nov 03, 2025 pp. 1270-1270 10.1182/blood-2025-1270

Abstract Background: Immune Thrombocytopenic Purpura (ITP) is an autoimmune condition characterized by isolated thrombocytopenia, with known...

Evaluation of real-world outcomes with zanubrutinib in patients with marginal zone lymphoma: Results from multicenter cohort study

Narendranath Epperla, Geoffrey Shouse, Jess Hatfield et al. Nov 03, 2025 pp. 4534-4534 10.1182/blood-2025-4534

Abstract Introduction: Zanubrutinib (zanu) received accelerated U.S. Food and Drug Administration (FDA) approval for patients (pts) with rel...

Dissecting mechanisms at an IKZF1 cis-regulatory element harboring ancestry-specific and cross-ancestry B-cell acute lymphoblastic leukemia risk variation

Luana Messa, Lara Wahlster, Andrew Lee et al. Nov 03, 2025 pp. 3252-3252 10.1182/blood-2025-3252

Abstract B-cell acute lymphoblastic leukemia (B-ALL) is the most common pediatric cancer, with Hispanic/Latino (H/L) children in the United...

Revisiting the role of second allogeneic HCT for post-transplant relapse in acute lymphoblastic leukemia: Comparative outcomes in the era of targeted therapies

Jaehyun Ahn, Daehun Kwag, Gi June Min et al. Nov 03, 2025 pp. 1548-1548 10.1182/blood-2025-1548

Abstract Background: Relapse after allogeneic hematopoietic cell transplantation (HCT) remains the leading cause of treatment failure in adu...

Correlation between efficacy, clonal dynamics evolution, and development of bone marrow failure in PNH/AA syndrome treated with complement inhibitors: A single-center cohort study

Chen Yang, Bing Han Nov 03, 2025 pp. 4987-4987 10.1182/blood-2025-4987

Abstract Objective: To investigate the correlation between therapeutic response patterns to complement inhibitors, clonal dynamics changes,...

Cladribine based salvage chemotherapy in AML patients with persistent or recurrent disease after venetoclax/HMA

Sameem Abedin, Guru Subramanian Guru Murthy, Karen-Sue Carlson et al. Nov 03, 2025 pp. 5238-5238 10.1182/blood-2025-5238

Abstract INTRODUCTION In adults with acute myeloid leukemia (AML), the combination of venetoclax (ven) and a hypomethylating agent (HMA) rep...

Clinical characteristics and comutational landscape of CSF3R mutations in acute myeloid leukemia

Lara Wiechers, Rabea Mecklenbrauck, Razif Gabdoulline et al. Nov 03, 2025 pp. 1718-1718 10.1182/blood-2025-1718

Abstract Background Mutations in the colony stimulating factor 3 receptor (CSF3R) are the hallmark of chronic neutrophilic leukemia (CNL) an...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page